{"id":937810,"date":"2026-02-18T08:20:08","date_gmt":"2026-02-18T13:20:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/"},"modified":"2026-02-18T08:20:08","modified_gmt":"2026-02-18T13:20:08","slug":"pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/","title":{"rendered":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific\u00a0<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Enables\u00a0scalable, automated manufacturing of diverse immune cell therapies using proprietary\u00a03D\u00a0expansion technology\u00a0<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Strengthens positioning in China\u2019s growing cell therapy market and supports cross-border partnerships\u00a0<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p>HAIFA, Israel, Feb.  18, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Pluri Inc.<\/strong>\u00a0(\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d, \u201cour\u201d\u00a0or \u201cus\u201d) (Nasdaq and TASE: PLUR\u00a0),\u00a0a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today\u00a0announces\u00a0that the China National Intellectual Property Administration (CNIPA) has\u00a0granted\u00a0Pluri Biotech Ltd., a wholly owned subsidiary of Pluri,\u00a0a\u00a0patent\u00a0covering\u00a0its proprietary 3D\u00a0immune cell expansion and activation technology.\u00a0<\/p>\n<p>The\u00a0patent, titled \u201cSystem and Methods for Immune Cells Expansion and Activation in Large Scale\u201d\u00a0(Patent No. Cn 119301238 b),\u00a0expands\u00a0Pluri\u2019s\u00a0global\u00a0intellectual property\u00a0(IP) portfolio,\u00a0including granted patents in the United States\u00a0and\u00a0additional\u00a0granted patents in Japan, Korea,\u00a0Australia\u00a0and Israel.\u00a0The expanded portfolio supports the Company\u2019s strategy to pursue global collaboration and licensing agreements for immune cell therapy products built on\u00a0Pluri\u2019s\u00a0automated, large-scale manufacturing platform.\u00a0<\/p>\n<p>The patent family covers large-scale production of diverse immune cell types, both unmodified and genetically modified, across multiple therapeutic areas. The platform enables expansion of cell types spanning lymphoid and myeloid lineages, including conventional and unconventional T cells (such as MAIT), Natural Killer (NK) cells, Tumor Infiltrating Lymphocytes (TIL), and Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) engineered variants.\u00a0<\/p>\n<p>Securing this new patent in China comes at a pivotal moment for the country\u2019s rapidly\u00a0expanding cell therapy landscape. China has\u00a0emerged\u00a0as one of the world\u2019s most dynamic markets for CAR-T and advanced cell therapies,\u00a0driven by growing clinical adoption, expanding manufacturing infrastructure, and increased investment.\u00a0Protecting\u00a0Pluri\u2019s\u00a0IP in China not only strengthens our global portfolio but strategically positions us to\u00a0participate\u00a0and contribute to one of the fastest-growing ecosystems worldwide.\u00a0<\/p>\n<p>Pluri\u2019s\u00a0patented 3D platform addresses these industry\u00a0bottlenecks and\u00a0is designed\u00a0to\u00a0enable\u00a0mass production through a unique bioreactor system that mimics the human lymph node environment to expand\u00a0billions of\u00a0immune cells. We believe that this approach significantly enhances cost-efficiency by reducing the prohibitive expenses typically associated with traditional cell therapy production, a critical requirement for the high-volume Chinese pharmaceutical market. Furthermore, we believe that the platform ensures rigorous quality control through a fully automated, closed-loop process that\u00a0maintains\u00a0batch-to-batch consistency and cell integrity at an industrial scale.\u00a0<\/p>\n<p>\n        <em>A Strategic Bridge for Global Pharma\u00a0<\/em>\n      <\/p>\n<p>With patent protection across the U.S., China, Japan, Korea,\u00a0Australia\u00a0and Israel, Pluri provides an \u201cIP Bridge\u201d for partners developing therapies on its platform across the world\u2019s primary healthcare markets. We believe that this broad coverage supports a unified framework for international licensing and development, helping global pharma companies\u00a0operate\u00a0in China with greater confidence, while enabling Chinese biotech leaders to pursue global expansion. By protecting key manufacturing methods in both CNIPA and U.S. Patent and Trademark Office jurisdictions,\u00a0Pluri\u2019s\u00a0cross-continental defensibility can potentially reduce partnering risk and strengthen high-value collaborations where scalability, quality consistency and IP protection are critical to commercial success.\u00a0<\/p>\n<p>\u201cWe believe that securing patent\u00a0protection\u00a0in China,\u00a0one of the\u00a0most dynamic\u00a0cell therapy markets\u00a0globally,\u00a0validates\u00a0the\u00a0novelty and\u00a0scalability\u00a0of\u00a0our technology,&#8221; said\u00a0Yaky Yanay, chief Executive Officer and President of Pluri. &#8220;Together\u00a0with our granted patents in the U.S., Japan, Korea, Australia and Israel, our goal is to offer partners a\u00a0globally protected\u00a0manufacturing platform\u00a0capable of supporting large-scale immune cell production.&#8221;\u00a0<\/p>\n<p>\n        <strong>About Pluri<\/strong>\u00a0<br \/>Pluri\u2122 is a biotechnology company pioneering mass-scale cell expansion and\u00a0biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine,\u00a0foodtech,\u00a0agtech,\u00a0aesthetics\u00a0and offers Contract Development and Manufacturing Organization (CDMO) services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ONI3yHPlFBLtEg1_4r5n_hg6zqPTK1-FiuY48p6_5g7PUt63NrwuX1FKPUKRhxfC-VEVm25NQivW533jwhFdFEFqXZ0KquVPc9larjzAZfU=\" rel=\"nofollow\" target=\"_blank\">www.pluri-biotech.com<\/a>\u00a0or follow Pluri on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2pmp3a6-C-VIQXDxtI_GAR-uqLbUCwBajvH17ZRZqn6S-v6eaSHNBHwQ45BczABz5JvZpwmV4kgZtIZHS8DiFxRDuTv4rdSCqqWpRtbomS-IXUTKEromz3jPCycobLQq\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gFVfLMhQB0zxkzOFQUiV6qulfKpFoLkDWXMAzZiibsTqejXwWBXezVnLIVQyj0jsTrYTxXWmJGYCGopm2R0xUQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.\u00a0<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong>\u00a0<br \/>This\u00a0press\u00a0release\u00a0contains\u00a0express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the potential benefits to the Company from the new patent grant in China, including strengthening of its positioning in China and the support of cross border partnerships, global collaborations and licensing agreements;; the capacity of its 3D platform to address industry bottlenecks and enable mass production of immune cells, including MAIT cells; the potential for cost-efficiency, quality control in the Chinese pharmaceutical market, batch to batch consistency and cell integrity at an industrial scale; the belief that Pluri\u2019s\u00a0cross-continental defensibility can reduce partnering risk and strengthen high-value collaborations; the novelty and scalability of the Company\u2019s technology;; the company\u2019s ability to pursue collaborations with Chinese and global pharma companies ; the expected growth and investment trends in the Chinese biotech and cell therapy markets; and the potential impact of its technology on global healthcare solutions. These forward-looking statements and their implications are based on the current expectations of\u00a0Pluri\u2019s\u00a0management only and are subject to\u00a0a number of\u00a0factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially: the expected benefits from the patent grant may not be realized as anticipated;\u00a0Pluri may encounter changes in technology or market conditions; the company may face challenges in scaling its technology or securing commercial partnerships; regulatory developments in China or other jurisdictions could impact commercialization efforts; its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; and intensified competition in the cell therapy and immuno-oncology space. Except as otherwise required by law, Pluri undertakes no obligation to\u00a0publicly release\u00a0any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri,\u00a0reference is\u00a0made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission.\u00a0<\/p>\n<p>\n        <strong>Contacts<\/strong>\u00a0<br \/>Investors:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PUKKUNNIGiTIwroAFJ2gYq2H8ntGeYrOVaI4Uzgi_FDCMscL3ZWwDKFNAsxzGQTkFbs5hKkEIFq8Z18xGEGRY9-tEnX_-NWvMLNSmrWR2tDNlRyQMbQneTaqIL7sVxotxz1luKsJLJb1oGyg64y6dA==\" rel=\"nofollow\" target=\"_blank\">investor.relations@pluri-biotech.com<\/a>\u00a0\u00a0<br \/>Israel Media:\u00a0Gali Raz at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EV7xD0wNRYJOXhhCW5GdRlQQEQ3wV78-4QCUA-RC-Aweo2WWZMmwvIh39d4Lg9OCq_vNzzlO3YUrjv3sFjKIXrEWzCqK0rM1ZBhWbfZVn6pnmKlSxqG1bqG7ymbGT6m5\" rel=\"nofollow\" target=\"_blank\">gali.raz@pluri-biotech.com<\/a>\u00a0\u00a0<br \/>U.S. Media: Berry Brady at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VzW_CImZpxQdKzlkfWGY_lO6p3IF52pCbHTeSWekldQlda-Vd2j1kq6U7Mz0fTsuykNcZXAMhdvt557FxCFIbhlNU-U6rM8NF08QSs918Uw=\" rel=\"nofollow\" target=\"_blank\">berry@quantum-corp.com<\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTZlNmFmYjEtZmM1OS00MTk0LTlkOTgtYTIyZTMwNTE3NzAwLTEwMjkxNjktMjAyNi0wMi0xOC1lbg==\/tiny\/Pluri-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific\u00a0 Enables\u00a0scalable, automated manufacturing of diverse immune cell therapies using proprietary\u00a03D\u00a0expansion technology\u00a0 Strengthens positioning in China\u2019s growing cell therapy market and supports cross-border partnerships\u00a0 HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Pluri Inc.\u00a0(\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d, \u201cour\u201d\u00a0or \u201cus\u201d) (Nasdaq and TASE: PLUR\u00a0),\u00a0a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today\u00a0announces\u00a0that the China National Intellectual Property Administration (CNIPA) has\u00a0granted\u00a0Pluri Biotech Ltd., a wholly owned subsidiary of Pluri,\u00a0a\u00a0patent\u00a0covering\u00a0its proprietary 3D\u00a0immune cell expansion and activation technology.\u00a0 The\u00a0patent, titled \u201cSystem and Methods for Immune Cells Expansion and Activation in Large Scale\u201d\u00a0(Patent No. Cn 119301238 b),\u00a0expands\u00a0Pluri\u2019s\u00a0global\u00a0intellectual property\u00a0(IP) portfolio,\u00a0including granted patents in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937810","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific\u00a0 Enables\u00a0scalable, automated manufacturing of diverse immune cell therapies using proprietary\u00a03D\u00a0expansion technology\u00a0 Strengthens positioning in China\u2019s growing cell therapy market and supports cross-border partnerships\u00a0 HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Pluri Inc.\u00a0(\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d, \u201cour\u201d\u00a0or \u201cus\u201d) (Nasdaq and TASE: PLUR\u00a0),\u00a0a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today\u00a0announces\u00a0that the China National Intellectual Property Administration (CNIPA) has\u00a0granted\u00a0Pluri Biotech Ltd., a wholly owned subsidiary of Pluri,\u00a0a\u00a0patent\u00a0covering\u00a0its proprietary 3D\u00a0immune cell expansion and activation technology.\u00a0 The\u00a0patent, titled \u201cSystem and Methods for Immune Cells Expansion and Activation in Large Scale\u201d\u00a0(Patent No. Cn 119301238 b),\u00a0expands\u00a0Pluri\u2019s\u00a0global\u00a0intellectual property\u00a0(IP) portfolio,\u00a0including granted patents in &hellip; Continue reading &quot;Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T13:20:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent\",\"datePublished\":\"2026-02-18T13:20:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/\"},\"wordCount\":1102,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/\",\"name\":\"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\",\"datePublished\":\"2026-02-18T13:20:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/","og_locale":"en_US","og_type":"article","og_title":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk","og_description":"Expands patent protection across major global pharmaceutical markets, including the U.S., China and Asia-Pacific\u00a0 Enables\u00a0scalable, automated manufacturing of diverse immune cell therapies using proprietary\u00a03D\u00a0expansion technology\u00a0 Strengthens positioning in China\u2019s growing cell therapy market and supports cross-border partnerships\u00a0 HAIFA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) &#8212; Pluri Inc.\u00a0(\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d, \u201cour\u201d\u00a0or \u201cus\u201d) (Nasdaq and TASE: PLUR\u00a0),\u00a0a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today\u00a0announces\u00a0that the China National Intellectual Property Administration (CNIPA) has\u00a0granted\u00a0Pluri Biotech Ltd., a wholly owned subsidiary of Pluri,\u00a0a\u00a0patent\u00a0covering\u00a0its proprietary 3D\u00a0immune cell expansion and activation technology.\u00a0 The\u00a0patent, titled \u201cSystem and Methods for Immune Cells Expansion and Activation in Large Scale\u201d\u00a0(Patent No. Cn 119301238 b),\u00a0expands\u00a0Pluri\u2019s\u00a0global\u00a0intellectual property\u00a0(IP) portfolio,\u00a0including granted patents in &hellip; Continue reading \"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-18T13:20:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent","datePublished":"2026-02-18T13:20:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/"},"wordCount":1102,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/","name":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=","datePublished":"2026-02-18T13:20:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NjY2MyM3NDMxNjk1IzIwMTc1OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pluri Secures Global IP Position with China Patent\u00a0Grant\u00a0for Large-Scale Immune Cell Expansion,\u00a0Complementing\u00a0Prior U.S. Patent"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937810"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937810\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}